Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Simone De Castro Resende Franco"'
Autor:
Carla Zanchetta, Lauro José Gregianin, Mariana Bohns Michalowski, Ana Luiza Melo Rodrigues, Samantha Nichele, Neysimelia Costa Villela, Virginio Fernandes, Carla Nolasco Monteiro Breviglieri, Ana Karine Vieira, Paola Azenha Milani Soriano, Simone de Castro Resende Franco, Renata Fittipaldi Guimaraes, Liane Esteves Daudt, Victor Gottardello Zecchin, Maura Ikoma-Colturato, Maria Gabriela Matos, Laila Rigolin Fortunato, Cinthya Rocha Carvalho, Julia Lopes Garcia, RV Gouveia, Maria Lucia Lee, Cilmara Kuwahara, Juliana Folloni Fernandes, Gustavo Zamperlini, Gabriele Zamperlini Netto, Raul C. Ribeiro, Ana Maria Marinho da Silva, Natalia Maria Tavares Ferreira Borges, Monica Cypriano, V.C. Ginani, Antonio Vaz de Macedo, Luciana dos Santos Domingues, Alessandra Gomes, Paulo Henrique dos Santos Klinger, Luiz Guilherme Darrigo Junior, Antonella Zanette, Fernanda Lima Lelis, Carmem Bonfim, Rita de Cássia Barbosa Tavares, Karoline Helena Silva da Silva, Cláudio Galvão de Castro Junior, Adriana Seber, Patrícia Shimoda Ikeuti
Publikováno v:
JBMTCT. 2:138-146
THE BRAZILIAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (SBTMO) PRESENTS THE BRAZILIAN GUIDELINES ON HEMATOPOIETIC STEM CELL TRANSPLANTATION
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::557dfe34213f2a3d613ce719d369cda7
https://doi.org/10.46765/2675-374x.2021v4n1p138-146
https://doi.org/10.46765/2675-374x.2021v4n1p138-146
Autor:
Gustavo Zamperlini, Simone de Castro Resende Franco, RV Gouveia, Patrícia Shimoda Ikeuti, Neysimelia Costa Villela, Luiz Fernando Lopes
Publikováno v:
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY. 2:127
MDS in children is a rare group of hematopoietic stem cell clonal disorder. Allogeneic HSCT is the only curative treatment. HLA typing and the search for a compatible donor must be carried out upon diagnosis, for all patients. However, patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::259f01e6548e4582ec02128da2152862
https://doi.org/10.46765/2675-374x.2021v2n4p127
https://doi.org/10.46765/2675-374x.2021v2n4p127
Autor:
Neysimelia Costa Villela, Gustavo Zamperlini, Patrícia Shimoda Ikeuti, Roseane Vasconcelos Gouveia, Simone De Castro Resende Franco, Luiz Fernando Lopes
Publikováno v:
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY. 2:129
In addition to the chronic myeloid leukemia (CML) BCR-ABL1+, classic myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia and primary myelofibrosis. These have a very low incidence in the pediatric age group and there is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1368f08efe3c911ac3bf427287795786
https://doi.org/10.46765/2675-374x.2021v2n4p129
https://doi.org/10.46765/2675-374x.2021v2n4p129
Autor:
RV Gouveia, Neysimelia Costa Villela, Luiz Fernando Lopes, Patrícia Shimoda Ikeuti, Simone de Castro Resende Franco, Gustavo Zamperlini
Publikováno v:
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY. 2:128
Juvenile Myelomonocytic Leukemia (JMML) is a clonal hematopoietic disorder that usually occurs in early childhood, characterized by hyperactivation of the RAS signaling pathway. About 90% of patients have mutations in 1 of 5 genes (PTPN11, NRAS, KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05434308db3a887b48093fa7caf6efcf
https://doi.org/10.46765/2675-374x.2021v2n4p128
https://doi.org/10.46765/2675-374x.2021v2n4p128
Autor:
Liane Esteves Daudt, Carmem Bonfim, Mary E.D. Flowers, Luiz Guilherme Darrigo, Juliana Folloni Fernandes, Adriana Seber, Vergilio A.R. Colturato, Leonardo Javier Arcuri, Victor Zecchin, Simone de Castro Resende Franco
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S439-S440
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3462774763a3ae1104a6270eac160242
https://doi.org/10.1016/j.bbmt.2017.12.529
https://doi.org/10.1016/j.bbmt.2017.12.529